Astrazeneca Share Discussion Threads

[philanderer] 05/9/2024 17:35

Market report

AstraZeneca fell 2.7%.

AstraZeneca told the Financial Times that a ‘small number’ of its employees are under investigation by police in China, following a report they had been detained over possible infringement of data privacy laws and importing unlicensed medications.

Police in Shenzhen have detained five current and former employees over the collection of patient data and the distribution of a liver cancer drug that had not been approved in the country, Bloomberg reported earlier on Thursday.

[philanderer] 05/9/2024 13:53

Uncertainty........ Not good.

[1jat] 05/9/2024 12:32

You never know how these investigations will fall out.
It is said to relate to an unapproved liver cancer drug….which you think would be an isolated set of circumstances….but with China, there is always the prospect of a political crackdown of some sorts…..it will take time to see whether there are any consequences for the company.

[max euwe] 05/9/2024 10:50

News says AZN employees under investigation in China for potential illegal acts.

[suetballs] 05/9/2024 10:04

We've had a very good run recently.
Suet

[philanderer] 05/9/2024 09:58

Goldman Sachs raises AstraZeneca price target to 15,914 (15,756) pence - 'buy'

[diku] 27/8/2024 07:14

Second round of inflation coming?...

[geckotheglorious] 23/8/2024 14:31

That's because they are envious & resentful of those who work hard and save to better themselves.

Always been the way.

Energy bills up 10% in October

Taxes to be raised in October budget - ones to hit those multi millionaires (many of whom have left, or are leaving) and the burden will once again fall on the middle classes.

[suetballs] 23/8/2024 13:29

I just hope that a compromise can be made.
Labour just seem hell bent on punishing anybody who has anything.
Can't wait for the budget!
Suet

[philanderer] 23/8/2024 13:12

Financial Times:

AstraZeneca has warned it could relocate its vaccine manufacturing site from Merseyside to Philadelphia after the government weighs plans to cut state aid promised to the project

[philanderer] 20/8/2024 22:51

The Telegraph

Questor: This pharma giant is set to beat FTSE 100 during bull and bear markets


Questor says: buy

Ticker: AZN

Share price (GBP): 13,102p

[smcni1968] 16/8/2024 13:58

They are advancing the obesity pill to phase 2 so they think it works good enough... the CEO at one stage said they are planning to sell it at a cheap and cheerful price to appeal to casual weight losers

[philanderer] 15/8/2024 23:01

AstraZeneca shares hit a record high as US fast-tracks its blockbuster cancer drug Imfinzi


Daily Mail

[philanderer] 14/8/2024 13:49

Blow to AstraZeneca vaccine project as Reeves plans funding cuts

Chancellor reportedly seeking to cut £20m from the £65m promised by Hunt to Merseyside manufacturing plant

[philanderer] 13/8/2024 18:42

Indeed :-)

[holts] 13/8/2024 16:44

And it is .

[philanderer] 12/8/2024 23:37

MARKET REPORT: AstraZeneca tipped to become first £200bn British firm


Daily Mail

[philanderer] 29/7/2024 23:03

NHS watchdog blocks AstraZeneca breast cancer drug

[philanderer] 29/7/2024 09:49

LBBW raises AstraZeneca price target to 13,500 (13,300) pence - 'buy'

Goldman Sachs raises AstraZeneca price target to 15,756 (15,131) pence - 'buy'

[the white house] 29/7/2024 08:25

Robust results & a couple of decent late stage updates. Time to add

[philanderer] 25/7/2024 11:28

Market report


One stock that fell victim to good not being ‘good enough’, XTB analyst Kathleen Brooks said, was AstraZeneca.

‘The market is scrutinizing earnings reports and punishing pockets of weakness,’ Brooks added, as the analyst said higher than expected costs may have been behind the 3.3% fall in the company’s shares.

The Cambridge-based pharmaceutical firm said total revenue in the first half of 2024 surged 15% to $25.62 billion from $22.30 billion. Pretax profit jumped 19% to $5.29 billion from $4.35 billion.

For the second-quarter alone, revenue climbed 13% $12.94 billion, and pretax profit was 15% higher at $2.40 billion.

Looking to the full-year, the pharmaceutical firm now expects total revenue and core EPS to grow by a ‘mid teens percentage’ at constant currency, its view upgraded from a previously expected ‘low double-digit to low teens rise’.

[philanderer] 25/7/2024 09:21

On first look no disaster..


AstraZeneca lifted its full-year guidance as it reported an 18% increase in total revenue for the first half to $25.6bn, driven by significant growth in product sales and alliance revenue.

The FTSE 100 pharmaceuticals giant saw 22% growth in revenue from oncology, CVRM, and R&I, while rare disease revenue grew by 15%, with a core operating margin of 33% and a core earnings per share increase of 5% to $4.03.

AstraZeneca declared a seven-cent increase in its interim dividend and raised its full-year 2024 guidance, expecting mid-teens percentage growth in total revenue and core earnings per share at constant exchange rates.

[philanderer] 25/7/2024 09:01

That's a rubbish response.

-3.3%

[holts] 25/7/2024 07:52

Glad there wasn’t bad news